Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NCC to build 129 rental apartments in Älvsjö

In partnership with Familjebostäder, NCC will construct 129 rental apartments close to the new Älvsjöstaden city district, south of Stockholm. The order value is approximately SEK 300 million.Älvsjöstaden is a major urban development area in Älvsjö, comprising a total of approximately 1,500 housing units in three phases. Disused industrial land is to be transformed into a city block in close proximity to commuter trains. “We are pleased that our cooperation with Familjebostäder is growing and that we have had the possibility to work together from an early stage to secure a

Read original

Sivers IMA wins SEK7.3m follow-up order from Fortune 100 customer

Sivers IMA Holding AB (Nasdaq First North: SIVE) today announced that its subsidiary, CST Global, received a new order worth SEK7.3m from an existing, US-based Fortune 100 customer.The order is in addition to existing framework orders CST Global has had with the same company.Sivers IMA Holding AB (Nasdaq First North: SIVE) today announced that its subsidiary, CST Global, received a new order worth SEK7.3m from an existing, US-based Fortune 100 customer.The order is in addition to existing framework orders CST Global has had with the same company.  The new contract is for the supply of

INTERIM REPORT Q2 2019

SummaryFinancial overview April 1 – June 30, 2019  · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 171.9 M (loss: 144.6) · Loss per share, before and after dilution, was SEK 3.52 (loss: 3.30) · On June 30 cash and cash equivalents amounted to SEK 626.8 M (568.2) Significant events during the period April 1 – June 30, 2019  · In April, melflufen was granted additional patent protection in the US until 2033 · In April it was announced that the last patient in the OCEAN trial is estimated to be enrolled during Q1 2020 · In May it was announced

Herantis Pharma Plc announces half year financial report January 1 - June 30, 2019 (unaudited)

Herantis Pharma Plc Company release August 28, 2019 at 9:00am Herantis Pharma Plc announces half year financial report January 1 - June 30, 2019 (unaudited) · Randomized clinical studies in Parkinson’s and lymphedema proceed as planned · Pipeline expansion with next generation xCDNF Highlights January-June 2019 · In March, Herantis Pharma Plc (“Herantis” or “Company”) issued 1,111,982 new shares for the subscription price of €5.20 per share in a directed issue, as authorized by the Extraordinary General Meeting. · In March, Herantis announced that its randomized

Systemair receives major order for Cruise Ships

Press Release, August 28, 2019 Systemair ABs (NASDAQ OMX Stockholm: SYSR) company in the Netherlands has received an order of air handling units, of a value of approx. EUR 3.3 million, from MAC Hamburg for three new ships. The new cruise ships will be built at Meyer Yard in Papenburg Germany. Systemair will deliver 150 air handling units per ship in phases from 2020 till 2022. The units will be placed both in public and technical areas of the ship.  "We are proud to be selected to deliver the units for these prestigious ships. Our factory in the Netherlands has more than 20 years’

First patient included in menstrual migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the first patient has been included in its Phase IIa trial of Sepranolone in menstrual migraine (MM). The study will include 80-90 patients and is expected to be completed by the end of 2020.“Standard prophylactic treatments have no efficacy in menstrual migraine. Sepranolone is the most highly targeted prophylactic treatment for menstrual migraine I’ve seen. The protocol for the study is extremely clear and the science highly promising. With 50 million women worldwide living with menstrual migraine the demand for this kind of

The path to 510(k) submission defined after FDA feedback

Biovica has completed the supplement II process which includes written feedback and physical meetings with the FDA in order to define the process for clinical validation for 510(k) submission for DiviTum®. Biovica also announces that an agreement with a leading oncology group has been signed. The agreement enables Biovica to analyze samples from a large, high impact, clinical trial within metastatic breast cancer. Biovica will use the results in the 510(k) FDA submission and has chosen to extend the time plan in order to include the results as an essential part of the submission.Based on

Annual General Meeting of Lagercrantz Group AB 27 August 2019

Resolutions including the following were passed by the Annual General Meeting held on August 27, 2019: Appropriation of the Company’s profit and dividend The Annual General Meeting adopted the Income Statement, the Balance Sheet, the Consolidated Income Statement and the Consolidated Balance Sheet for the fiscal year 2018/19. A dividend of SEK 2.50 per share was declared in accordance with the proposal of the Board of Directors. Thursday, 29 September 2019 is record day for receiving dividend that is expected to be paid out by Euroclear Sweden AB Tuesday, 3 September 2019.

Nixu Corporation’s growth ambition for 2020-2024

Nixu Corporation Press release on August 28, 2019 at 8.50 AM (EEST)European cybersecurity company, Nixu has announced today its growth ambition for the next five years, 2020 to 2024.In 2018, Nixu refreshed its strategy, according to which the company aims to be 1) the best workplace for cybersecurity professionals and 2) the trusted, go-to partner for cybersecurity services for digitalization in Northern Europe. Since its stock exchange listing in 2014, Nixu has grown with a compound annual growth rate of 27% from EUR 12 million to EUR 40 million over the five years. At the same time,

Refined operations, increased focus on near-term profitability and growth in rental business

From Q4 2018 and according to Nasdaq’s recommendation, SSM has applied the completed contract method, with retroactive application, for reporting housing cooperative projects.  Summary of April – June 2019 ·  Change of CEO, Mattias Lundgren, former CFO at NCC AB with many years’ experience in the housing and real estate industry appointed interim CEO on June 10, 2019.    ·  Repurchase of outstanding SSM bonds for a nominal value of 31.0 MSEK, volume-based average price at 70.4 percent.  ·  Net sales for projects run entirely by SSM totaled 20.4 MSEK (321.5).   ·  Operating

Skanska signs contract to build high school in Burien, Washington, USA for USD 113.5 M, about SEK 1.1 billion

Skanska has signed a contract with Highline Public Schools in Burien, Washington, USA to build a replacement high school. The contract value is USD 113.5 M, about SEK 1.1 billion, which will be included in the US order bookings for the third quarter 2019.Skanska will demolish the existing high school and build a new 22,000 square-meter replacement school, which will serve up to 1,500 students. The project includes general and specialty classrooms, a theater and black box drama classroom, career and technical education spaces, science classrooms, multiple gyms, and tennis courts.

Restatement of financial information according to IFRS 16

Clas Ohlson’s interim report for the first quarter 2019/20, to be published on 4 September 2019, is the first to be presented after the introduction of the new accounting standard IFRS 16. The purpose of this document is to facilitate comparison with historical periods.Information about the application of IFRS 16 and the expected effects on the balance sheet was presented in the Year-end Report 2018/19, published on 5 June 2019, and in the 2018/19 Annual Report, published on 1 July 2019. Leases for premises have single largest IFRS 16 impact The main impact of IFRS 16 on the Group’s

Nel ASA: Second quarter 2019 results

(Oslo, August 28, 2019) Nel ASA (“Nel”) reported revenues in the second quarter of 2019 of NOK 122.5 million (135.8), in line with company outlook, and an all-time high order backlog of NOK 568 million at the end of the quarter. Nel booked a provision of NOK 35 million to cover estimated cost, net of estimated insurance coverage, related to the incident at the Kjørbo hydrogen station, and is on-track getting stations back in operations. Nel reiterates the strong market outlook. “Nel ended the quarter with an all-time high order backlog and a solid pipeline of prospects, reflecting the

IRLAB to advance clinical development of IRL790 in LIDs based on in-depth analysis of positive Phase IIa results

IRLAB (Nasdaq First North Premier: IRLAB A) today announced that the in-depth analysis of the data from the recently concluded Phase IIa study of IRL790 in Parkinson’s patients with L-dopa induced dyskinesia (LIDs) brings further evidence of the drug candidate’s ability to significantly and meaningfully improve daytime movement quality. IRLAB has therefore decided to prioritize the LIDs indication in the development of IRL790. A Phase IIb/III study in this patient group is planned to start in the first half of 2020, as part of a pivotal clinical program towards market approval. The planned

Nel ASA: Secured location for low-cost electrolyzer manufacturing with infrastructure allowing for more than 1 GW/year capacity

(Oslo, 28 August 2019) Nel ASA (Nel, OSE:NEL) announces today that the company has secured a new location in Herøya Industrial Park (Herøya) for the planned expansion of manufacturing capacity of alkaline electrolyzers. The new location at Herøya provides a number of benefits, including a potential to further expand capacity to more than 1 GW/year. Besides manufacturing, the other functions related to alkaline electrolyzer operations will continue from Notodden. “We have been working closely with partners and stakeholders during 2019 with the expansion plans, and have finally concluded

Nel ASA: Invests in HyNet and receives purchase order for two hydrogen fueling stations in Korea

(Oslo, 28 August 2019) Nel Korea Co., Ltd., a subsidiary of Nel ASA (Nel, OSE:NEL) in Korea has made an investment in Hydrogen Energy Network Co., Ltd.(HyNet), and simultaneously received a purchase order for two H2Station® hydrogen fueling stations in Korea. "With a total of 10 H2Station® orders in Korea so far in 2019, it's quickly becoming one of our most important markets for fueling stations. We're happy that the effort we have put in through several years of good dialogue, good partnerships and establishing a local presence in Korea is bearing fruit. We can safely say we have had a

Products that prove their environmental credentials

Sustainably-sourced steel can help OEMs (Original Equipment Manufacturer) deliver climate-smart products and reduce their overall carbon footprint – and in turn attract environmentally conscious customers and respond to tightening legislation.The issue is particularly important for steel components as the steel industry represents more than eight percent of the world’s carbon dioxide emissions. The key to evaluating a product’s true carbon footprint is through a life cycle assessment of the environmental impacts at every step from raw material extraction, materials processing,

Read original

Finnish dairy innovation helps food manufacturers to cater to the needs of ageing adults

Seniors and their families want to invest in healthy ageing and happy later life. With Valio’s pure Nordic dairy ingredients and latest innovation, food manufacturers can add the benefits of phospholipids on cognitive health and create desirable functional food products for healthy ageing. Experience Valio at Food Ingredients Asia in Bangkok, Thailand, 11 - 13 September 2019As good nutrition has a scientifically proven link to healthy ageing, the expanding elderly population and their wellbeing provides great potential for the food industry. With the right innovations supporting healthy

BAUHAUS Museum Dessau: A new destination in BauhausLand

THE VIEW FROM THE DIRECTOR’s CHAIRAn armchair, a dress, and a collage: Many of the objects on display at the new Bauhaus Museum Dessau  have never been seen in public before. That is why the museum opening on September 8th is one of the major highlights of the celebrations marking the 100th birthday of the Bauhaus design movement. Like a soaring steel frame encased in glass, the building itself is eye-catching. Looking through the glass facade, Dessau’s city park is visible in one direction and the city center in the other; visitors feel part of the urban

Promore Pharma is granted a patent for LL-37 in Japan

STOCKHOLM, 27 August 2019 – Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the company was granted a patent in Japan for the usage of LL-37 for treating chronic wounds.The Japanese patent authority has formally granted the patent “New Treatment of Chronic Ulcers” with LL-37. The patent is valid until 19 November 2034. Patents within the same patent family have previously been granted in the USA. In the territories Europe, Russia, Canada, South America , other Asia and South Africa the patent review is in an early stage. "This is an

THQ Nordic publishes Annual Report 2018/19

THQ Nordic AB (publ) today publishes its Annual Report for the extended financial year 2018/19. The Annual Report is enclosed this press release and is also available for downloading on: www.thqnordic-investors.com/en/financial-reportsIf you require a printed version, please contact ir@thqnordic.com. The Annual Report is also available in Swedish for downloading on: www.thqnordic-investors.com/finansiella-rapporter For additional information, please contact:Lars Wingefors, Co-Founder and Group-CEOTel: +46 708 471 978E-mail: lwingefors@thqnordic.com About THQ Nordic THQ

YIT Corporation: SHARE REPURCHASE 27.8.2019

YIT Corporation ANNOUNCEMENT  27.8.2019 YIT Corporation: SHARE REPURCHASE 27.8.2019 In the Helsinki Stock Exchange Trade date           27.8.2019Bourse trade         BuyShare                  YITAmount             50 000 SharesAverage price/ share    5,0476 EURTotal cost            252 380,00 EUR YIT Corporation now holds a total of 2 222 783 sharesincluding the shares repurchased on 27.8.2019 On behalf of YIT Corporation Nordea Bank Oyj Janne Sarvikivi

Sales of Miris Human Milk Analyzer in the U.S. increasing

As milk analyzer company Miris received clearance by US Food and Drug Administration (FDA) to market its Miris Human Milk Analyzer™ (Miris HMA™) in December last year, clinicians in the U.S. for the first time have access to a test to analyze the nutrients in breast milk. With the FDA clearance Miris has seen an increased demand for the instrument and the development of target fortification strategies.During the first half of 2019, Miris has focused on entering the U.S. market. During the first six months of 2019 Miris sold and installed two HMA units for clinical use in the U.S. Now, in

There are no items matching the current filter
There are no more items matching the current filter
Back to top